Immunocore Holdings Ownership

IMCR Stock  USD 30.46  0.31  1.03%   
Immunocore Holdings has a total of 49.35 Million outstanding shares. The majority of Immunocore Holdings outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Immunocore Holdings to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Immunocore Holdings. Please pay attention to any change in the institutional holdings of Immunocore Holdings as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunocore Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
To learn how to invest in Immunocore Stock, please use our How to Invest in Immunocore Holdings guide.

Immunocore Stock Ownership Analysis

About 94.0% of the company shares are owned by institutional investors. The book value of Immunocore Holdings was currently reported as 7.21. The company recorded a loss per share of 1.02. Immunocore Holdings had not issued any dividends in recent years. Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. Immunocore Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 324 people. To learn more about Immunocore Holdings call Bahija Jallal at 44 12 3543 8600 or check out https://www.immunocore.com.

Immunocore Holdings Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunocore Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunocore Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunocore Holdings insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Berman David M few days ago
Disposition of 28553 shares by Berman David M of Immunocore Holdings at 17.46 subject to Rule 16b-3
 
St Leger Tina Amber over a month ago
Acquisition by St Leger Tina Amber of 8476 shares of Immunocore Holdings subject to Rule 16b-3
 
Baker Bros. Advisors Lp over a month ago
Disposition of tradable shares by Baker Bros. Advisors Lp of Immunocore Holdings subject to Rule 16b-3
 
Travis Coy over three months ago
Acquisition by Travis Coy of 274033 shares of Immunocore Holdings at 29.5 subject to Rule 16b-3
 
Baker Bros. Advisors Lp over six months ago
Discretionary transaction by Baker Bros. Advisors Lp of 674261 shares of Immunocore Holdings subject to Rule 16b-3
 
Baker Bros. Advisors Lp over six months ago
Discretionary transaction by Baker Bros. Advisors Lp of 674261 shares of Immunocore Holdings subject to Rule 16b-3
 
Herbst Roy Steven over six months ago
Disposition of 8676 shares by Herbst Roy Steven of Immunocore Holdings at 58.69 subject to Rule 16b-3
 
Berman David M over six months ago
Disposition of 28553 shares by Berman David M of Immunocore Holdings at 17.46 subject to Rule 16b-3
 
Baker Bros. Advisors Lp over six months ago
Discretionary transaction by Baker Bros. Advisors Lp of 1449226 shares of Immunocore Holdings subject to Rule 16b-3
 
Bell John Irving over six months ago
Acquisition by Bell John Irving of 14534 shares of Immunocore Holdings at 50.47 subject to Rule 16b-3
 
St Leger Tina Amber over a year ago
Disposition of 4375 shares by St Leger Tina Amber of Immunocore Holdings at 64.06 subject to Rule 16b-3
 
Bahija Jallal over a year ago
Acquisition by Bahija Jallal of 281819 shares of Immunocore Holdings at 70.5 subject to Rule 16b-3

Immunocore Holdings Outstanding Bonds

Immunocore Holdings issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunocore Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunocore bonds can be classified according to their maturity, which is the date when Immunocore Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Pair Trading with Immunocore Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunocore Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunocore Holdings will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Immunocore Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunocore Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunocore Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunocore Holdings to buy it.
The correlation of Immunocore Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunocore Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunocore Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunocore Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Immunocore Stock Analysis

When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.